Compare · ORKA vs TNFA
ORKA vs TNFA
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and TNF Pharmaceuticals Inc. (TNFA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TNFA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $6.73B.
- ORKA has hit the wire 12 times in the past 4 weeks while TNFA has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for TNFA).
- Company
- Oruka Therapeutics Inc.
- TNF Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $6.73B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 12
- 0
- Recent ratings
- 11
- 0
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $706,700 worth of shares (7,000 units at $100.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
Latest TNFA
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
- TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing
- TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form D filed by TNF Pharmaceuticals Inc.
- TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits